These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 1617997

  • 21. Effects of hepatic fibrosis on ofloxacin pharmacokinetics in rats.
    Wang H, Liao ZX, Chen M, Hu XL.
    Pharmacol Res; 2006 Jan; 53(1):28-34. PubMed ID: 16182555
    [Abstract] [Full Text] [Related]

  • 22. Pharmacokinetics of ofloxacin in severe chronic renal failure.
    Bandai H, Tsubakihara Y, Yamato E, Yokoyama K, Okada N, Nakanishi I, Iida N.
    Clin Ther; 1989 Jan; 11(2):210-8. PubMed ID: 2736567
    [Abstract] [Full Text] [Related]

  • 23. Pharmacokinetics of ampicillin in cirrhosis.
    Lewis GP, Jusko WJ.
    Clin Pharmacol Ther; 1975 Oct; 18(4):475-84. PubMed ID: 1164828
    [Abstract] [Full Text] [Related]

  • 24. Pharmacokinetics of cefotaxime and desacetyl-cefotaxime in cirrhosis of the liver.
    Höffken G, Lode H, Koeppe P, Ruhnke M, Borner K.
    Chemotherapy; 1984 Oct; 30(1):7-17. PubMed ID: 6319092
    [Abstract] [Full Text] [Related]

  • 25. Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects.
    Pentikäinen PJ, Välisalmi L, Himberg JJ, Crevoisier C.
    J Clin Pharmacol; 1989 Mar; 29(3):272-7. PubMed ID: 2723115
    [Abstract] [Full Text] [Related]

  • 26. [Pharmacokinetics of ofloxacin administered orally in elderly subjects with bronchial or urinary tract infections].
    Bardin C, Clavier M, Darchis JP, Chauvin M, Veyssier P, Farinotti R.
    Therapie; 1992 Mar; 47(1):35-9. PubMed ID: 1523592
    [Abstract] [Full Text] [Related]

  • 27. Bioavailability and pharmacokinetics of ofloxacin in healthy volunteers.
    Yuk JH, Nightingale CH, Quintiliani R, Sweeney KR.
    Antimicrob Agents Chemother; 1991 Feb; 35(2):384-6. PubMed ID: 2024973
    [Abstract] [Full Text] [Related]

  • 28. Furosemide disposition in cirrhosis.
    Verbeeck RK, Patwardhan RV, Villeneuve JP, Wilkinson GR, Branch RA.
    Clin Pharmacol Ther; 1982 Jun; 31(6):719-25. PubMed ID: 7075120
    [Abstract] [Full Text] [Related]

  • 29. Pharmacokinetics of oral brotizolam in patients with liver cirrhosis.
    Jochemsen R, Joeres RP, Wesselman JG, Richter E, Breimer DD.
    Br J Clin Pharmacol; 1983 Jun; 16 Suppl 2(Suppl 2):315S-322S. PubMed ID: 6661377
    [Abstract] [Full Text] [Related]

  • 30. Pharmacokinetics of ofloxacin after single and multiple intravenous infusions in healthy subjects.
    Farinotti R, Trouvin JH, Bocquet V, Vermerie N, Carbon C.
    Antimicrob Agents Chemother; 1988 Oct; 32(10):1590-2. PubMed ID: 3190187
    [Abstract] [Full Text] [Related]

  • 31. Temazepam clearance unaltered in cirrhosis.
    Ochs HR, Greenblatt DJ, Verburg-Ochs B, Matlis R.
    Am J Gastroenterol; 1986 Jan; 81(1):80-4. PubMed ID: 2867675
    [Abstract] [Full Text] [Related]

  • 32. Pharmacokinetics of levofloxacin after single and multiple oral doses in patients undergoing intermittent haemodialysis.
    Tsaganos T, Kouki P, Digenis P, Giamarellou H, Giamarellos-Bourboulis EJ, Kanellakopoulou K.
    Int J Antimicrob Agents; 2008 Jul; 32(1):46-9. PubMed ID: 18534825
    [Abstract] [Full Text] [Related]

  • 33. Pharmacokinetics of cimetidine in patients with liver disease.
    González-Martin G, Arancibia A, Fajuri M, Chesta J, Novoa X.
    Int J Clin Pharmacol Ther Toxicol; 1985 Jul; 23(7):355-8. PubMed ID: 4030163
    [Abstract] [Full Text] [Related]

  • 34. Safety and pharmacokinetics of single dose intravenous ofloxacin in healthy volunteers.
    Guay D, Tack K, Flor S.
    Int J Clin Pharmacol Res; 1991 Jul; 11(5):203-9. PubMed ID: 1814841
    [Abstract] [Full Text] [Related]

  • 35. Oral and intravenous pharmacokinetics of cimetidine in liver cirrhosis.
    Okolicsanyi L, Venuti M, Orlando R, Lirussi F, Nassuato G, Benvenuti C.
    Int J Clin Pharmacol Ther Toxicol; 1982 Oct; 20(10):482-7. PubMed ID: 7141756
    [Abstract] [Full Text] [Related]

  • 36. Pharmacokinetics and bioavailability of ranitidine in normal subjects and cirrhotic patients.
    Morichau-Beauchant M, Houin G, Mavier P, Alexandre C, Dhumeaux D.
    Dig Dis Sci; 1986 Feb; 31(2):113-8. PubMed ID: 3943439
    [Abstract] [Full Text] [Related]

  • 37. Pharmacokinetics of famotidine in normal subjects and in patients with chronic liver disease.
    Morgan MY, Stambuk D, Cottrell J, Mann SG.
    Aliment Pharmacol Ther; 1990 Feb; 4(1):83-96. PubMed ID: 2104076
    [Abstract] [Full Text] [Related]

  • 38. The pharmacokinetics of enalapril in patients with compensated liver cirrhosis.
    Baba T, Murabayashi S, Tomiyama T, Takebe K.
    Br J Clin Pharmacol; 1990 Jun; 29(6):766-9. PubMed ID: 2165799
    [Abstract] [Full Text] [Related]

  • 39. The effect of food or milk on the absorption kinetics of ofloxacin.
    Dudley MN, Marchbanks CR, Flor SC, Beals B.
    Eur J Clin Pharmacol; 1991 Jun; 41(6):569-71. PubMed ID: 1815968
    [Abstract] [Full Text] [Related]

  • 40. Pharmacokinetics of promazine in patients with hepatic cirrhosis--correlation with a novel galactose single point method.
    Hu OY, Tang HS, Sheeng TY, Chen TC, Curry SH.
    J Pharm Sci; 1995 Jan; 84(1):111-4. PubMed ID: 7714731
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.